Polymers and their engineered analogues for ocular drug delivery : Enhancing therapeutic precision
© 2024 Wiley Periodicals LLC..
Ocular drug delivery is constrained by anatomical and physiological barriers, necessitating innovative solutions for effective therapy. Natural polymers like hyaluronic acid, chitosan, and gelatin, alongside synthetic counterparts such as PLGA and PEG, have gained prominence for their biocompatibility and controlled release profiles. Recent strides in polymer conjugation strategies have enabled targeted delivery through ligand integration, facilitating tissue specificity and cellular uptake. This versatility accommodates combined drug delivery, addressing diverse anterior (e.g., glaucoma, dry eye) and posterior segment (e.g., macular degeneration, diabetic retinopathy) afflictions. The review encompasses an in-depth exploration of each natural and synthetic polymer, detailing their individual advantages and disadvantages for ocular drug delivery. By transcending ocular barriers and refining therapeutic precision, these innovations promise to reshape the management of anterior and posterior segment eye diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Biopolymers - (2024) vom: 05. Apr., Seite e23578 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Biswas, Arpon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chitosan |
|---|
| Anmerkungen: |
Date Revised 05.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/bip.23578 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37067278X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37067278X | ||
| 003 | DE-627 | ||
| 005 | 20240405234834.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240405s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/bip.23578 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM37067278X | ||
| 035 | |a (NLM)38577865 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Biswas, Arpon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polymers and their engineered analogues for ocular drug delivery |b Enhancing therapeutic precision |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 Wiley Periodicals LLC. | ||
| 520 | |a Ocular drug delivery is constrained by anatomical and physiological barriers, necessitating innovative solutions for effective therapy. Natural polymers like hyaluronic acid, chitosan, and gelatin, alongside synthetic counterparts such as PLGA and PEG, have gained prominence for their biocompatibility and controlled release profiles. Recent strides in polymer conjugation strategies have enabled targeted delivery through ligand integration, facilitating tissue specificity and cellular uptake. This versatility accommodates combined drug delivery, addressing diverse anterior (e.g., glaucoma, dry eye) and posterior segment (e.g., macular degeneration, diabetic retinopathy) afflictions. The review encompasses an in-depth exploration of each natural and synthetic polymer, detailing their individual advantages and disadvantages for ocular drug delivery. By transcending ocular barriers and refining therapeutic precision, these innovations promise to reshape the management of anterior and posterior segment eye diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a chitosan | |
| 650 | 4 | |a drug delivery | |
| 650 | 4 | |a ocular | |
| 650 | 4 | |a polymeric conjugates | |
| 650 | 4 | |a polymers | |
| 650 | 4 | |a synthetic polymers | |
| 700 | 1 | |a Kumar, Shivansh |e verfasserin |4 aut | |
| 700 | 1 | |a Choudhury, Abhijit Deb |e verfasserin |4 aut | |
| 700 | 1 | |a Bisen, Amol Chhatrapati |e verfasserin |4 aut | |
| 700 | 1 | |a Sanap, Sachin Nashik |e verfasserin |4 aut | |
| 700 | 1 | |a Agrawal, Sristi |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Anjali |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Sarvesh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Mukesh |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatta, Rabi Sankar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biopolymers |d 1965 |g (2024) vom: 05. Apr., Seite e23578 |w (DE-627)NLM000014648 |x 1097-0282 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:04 |g pages:e23578 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/bip.23578 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 04 |h e23578 | ||